Anvisa evaluates the use of Coronavac in children aged 3 years and over
The National Health Surveillance Agency (Anvisa) announced that last Thursday (6) it held several meetings to analyze the Butantan Institute's request to release the application of the vaccine against Covid-19 Coronavac in children and adolescents aged 3 to 17 years old.
The evaluation was divided into three parts: the first included the presentation of studies carried out by the Oswaldo Cruz Foundation ( Fiocruz ), then the data were discussed with external experts. Finally, Anvisa met with representatives from the Butantan Institute, specialists from Chile and Sinovac .
- Elderly person took more than 8 doses of Covid-19 vaccine in India
- More than 2.5 million cases of Covid-19 are reported worldwide for the 4th day in a row
- Covid-19 cases worldwide rose 70% last week, says WHO
The analyzes carried out by Anvisa had the participation of representatives from the Department of Infectology of the Brazilian Society of Pediatrics (SBP), the Brazilian Society of Infectious Diseases (SBI), the Brazilian Association of Public Health (Abrasco) and the Brazilian Society of Immunology (SBI).
The National Health Surveillance Agency stated that these meetings "are another step in the analysis of the vaccine" and the data presented "represent an advance in the work".
For now, Brazil only allows vaccines against Pfizer's Covid-19 to be given to minors. Recently, children aged 5 to 11 have also been added to the group of authorized.
The Butantan Institute requested authorization for the application of Coronavac in children and adolescents aged 3 to 17 years in December 2021, however, at the time, the Brazilian regulatory agency stated that the data provided were still insufficient to carry out the analysis and possible authorization.
Have you already watched the new videos of Olhar Digital on YouTube? Subscribe to the channel!
The post Anvisa evaluates the use of Coronavac in children aged 3 years and over first appeared in Olhar Digital .